论文部分内容阅读
用甲状腺片配合昆明山海棠治疗桥本氏甲状腺炎(HT)患者58例(A 组),单纯甲状腺片替代治疗HT 患者37例(B 组)。治疗前、后平均血清T_3、T_4和TSH 水平两组间无明显差异(P 值均>0.05)。平均血清TMAb 和TGAb 水平,A 组在治疗4.44±2.56月后较治疗前显著降低(P 值均<0.001);B 组在治疗8.27±4.99月后与治疗前比较无明显差异(P 值均>0.05)。昆明山海棠有希望通过降低血清TMAb 和TGAb水平阻止或减轻TH 患者甲状腺的病理损害,减缓甲状腺功能减退进程和减少甲状激腺素替代治疗剂量。
Fifty-eight patients (group A) with thyroid gland and Kunming Begonia were treated with Hashimoto’s thyroiditis (HT), and 37 patients with HT were treated by thyroid alone (group B). There was no significant difference between the two groups before and after treatment (P> 0.05). Mean serum levels of TMAb and TGAb were significantly lower in group A than those in group A at 44.42 ± 56.6 months after treatment (P <0.001). There was no significant difference in group B after treatment between 8.27 ± 4.99 months and before treatment (P> 0.05). It is hoped that Kunming Begonia could prevent or reduce the thyroid pathological damage, reduce the process of hypothyroidism and reduce the dose of thyroid hormone replacement therapy by decreasing serum TMAb and TGAb levels.